Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Pilot Randomized Controlled Clinical Trial to Improve Adherence Barriers for Adolescents with Type 1 Diabetes.

The Journal of pediatrics·2026

Same author

Commentary: Social drivers of health within the Pediatric Self-Management Model.

Journal of pediatric psychology·2026

Same author

Parental miscarried helping, self-efficacy, and treatment adherence among adolescents and young adults with epilepsy: A mediation model.

Epilepsy research·2026

Same author

Best Practices in Clinical Epilepsy Symposium | Mortality in Epilepsy: Challenges and Interventions.

Epilepsy currents·2026

Same author

Recruitment and retention of young adults with sickle cell disease.

Health care transitions·2026

Same author

Epilepsy journey 2.0 study design and methods: A randomized trial of an executive functioning intervention for adolescents with epilepsy.

Contemporary clinical trials communications·2026

Search research articles

Related Experiment Video

Updated: Aug 5, 2025

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

Published on: July 31, 2017

Demystifying a family-based epilepsy adherence problem-solving intervention: Exploring adherence barriers and

Desireé N Williford¹, Shanna M Guilfoyle^1,2, Avani C Modi^1,2

¹Cincinnati Children's Hospital Medical Center.

Clinical Practice in Pediatric Psychology

|March 27, 2023

Summary

This summary is machine-generated.

Families identified forgetting medication and routine changes as key barriers to adherence in pediatric epilepsy. Environmental cuing and positive reinforcement were common solutions, improving medication management for children.

Keywords:

children compliance forgetting qualitative seizures

More Related Videos

$Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note$

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Related Experiment Videos

Last Updated: Aug 5, 2025

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

Published on: July 31, 2017

$Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note$

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Area of Science:

Pediatric Neurology
Clinical Pharmacy
Behavioral Science

Background:

Medication adherence is crucial for managing pediatric epilepsy, yet significant barriers exist, impacting seizure control and quality of life.
Nonadherence in children with epilepsy is a common challenge for healthcare providers and families.
A tailored intervention was developed to address these specific adherence barriers.

Purpose of the Study:

To identify the primary barriers to medication adherence encountered by families of children with epilepsy.
To document the solutions families implemented to overcome these identified adherence challenges.
To inform clinical practice regarding effective adherence strategies in pediatric epilepsy management.

Main Methods:

A randomized controlled trial was conducted with young children (2-12 years) diagnosed with epilepsy and demonstrating nonadherence.
Participants in the treatment group received a manualized, family-tailored education and problem-solving intervention.
Adherence barriers and solutions were independently coded using thematic analysis from intervention session data.

Main Results:

The most frequent adherence barriers reported were Overall Forgetting (38-57%) and Routine Change Routine (14-24%).
Other identified barriers included Competing Activities, Opposition, and Running Out of Medication.
Families implemented solutions such as Environmental Cuing (29-50%), Positive Reinforcement (14-23%), and Multi-Pronged solutions.

Conclusions:

This study highlights significant adherence barriers and effective solutions identified by families managing pediatric epilepsy.
Findings offer practical guidance for healthcare teams to address medication adherence challenges in clinical settings.
The results underscore the importance of family-centered approaches in improving adherence for children with epilepsy.